Items starting with C

0.15-0.35g/L

PRU handbook in clinical Immunochemistry . A.Milford Ward. J.Sheldon et al 9th edition. 2007

Negative

Normal values <5 mg/L.

0.2-0.6g/L

Source : Abbott Diagnostics

Neonate (<4wks)  2.0-2.7 mmol/L

4wks-16yrs          2.2-2.7 mmol/L

Adult                   2.2-2.6 mmol/L

(Source : Pathology Harmony Recommendations)

Clinical Cut offs (New Guidance in place 16/07/2026)

Adults (Individuals 16 and over)

FCAL <100 ug/g : Not indicative of  GI Inflammation. Consider IBS or alternative diagnoses.

FCAL 100-250 ug/g : Indeterminate. Suggest repeating in 2-4 weeks if clinical concern remains or relevant family history. NSAIDs/PPIs should be stopped 2 weeks prior to sample collection. If repeat result also indeterminate suggest referral.

FCAL >250 ug/g : Indicative of GI inflammation, suggest referral.

Paediatrics (children <16 years old)

FCAL <50 ug/g - Not indicative of GI Inflammation

FCAL 50-150 ug/g : No further action needed. Consider repeat if symptoms worsen.

FCAL 151-250 ug/g : Indeterminate. Suggest repeating in 4 weeks if clinical concern remains or relevant family history. NSAIDs/PPIs should be stopped 2 weeks prior to sample collection. If repeat result also indeterminate suggest referral.

FCAL >250 ug/g : Indicative of GI inflammation, although false positives can occur in patients with high BMI. Suggest referral.

Population Reference Range used historically at BHH < 30 kU/L.

Manufacturers reference data. Roche Diagnostics June 2006:

593 pre- and post-menopausal healthy females yielded a 95th centile value of 35 kU/L.
It is suggested that a value of > 35 kU/L indicates that disease may still be present when used in the context of detection of residual or recurrent ovarian carcinoma following first line treatment.

<37U/mL (Source: Abbott Kit insert)

Therapeutic range: 4-12 mg/L

Source : Pathology Harmony Recommendations

Nystagmus, ataxia and drowsiness occur at levels above 12 mg/L and more serious toxicity above 15 mg/L.